BamSEC and AlphaSense Join Forces
Learn More

Petros Pharmaceuticals Inc. – Material Contracts

OTC: PTPI    
Share price (3/26/26): $0.01    
Market cap (3/26/26): $297 thousand

Material Contracts Filter

EX-10.1
from 10-Q 12 pages Executive Compensation Agreement
12/34/56
EX-10.1
from 8-K 2 pages Third Amendment to Amended and Restated Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan
12/34/56
EX-10.20
from 10-K 4 pages Form of Amendment Agreement
12/34/56
EX-10.19
from 10-K 5 pages Termination Agreement
12/34/56
EX-10.1
from 8-K 36 pages Securities Purchase Agreement
12/34/56
EX-10.20
from S-1/A 31 pages Securities Purchase Agreement
12/34/56
EX-10.20
from S-1/A 32 pages Securities Purchase Agreement
12/34/56
EX-10.23
from S-1/A 2 pages Second Amendment to Amended and Restated Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan
12/34/56
EX-10.22
from S-1/A 4 pages Lock-Up Agreement
12/34/56
EX-10.20
from S-1/A 31 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 5 pages Amendment Agreement
12/34/56
EX-10.1
from 10-Q 5 pages Amendment Agreement
12/34/56
EX-10.1
from 8-K 3 pages Offer Letter Amendment
12/34/56
EX-10.1
from 8-K 5 pages Amendment Agreement
12/34/56
EX-10.1
from 8-K 5 pages Omnibus Waiver and Amendment
12/34/56
EX-10.1
from 8-K 2 pages First Amendment to Amended and Restated Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan
12/34/56
EX-10.2
from 8-K 29 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 47 pages Securities Purchase Agreement
12/34/56
EX-10.5
from 10-Q 31 pages ​ ​ ​ Proposal # C-Crc-286511-R3 ​ Metuchen Pharmaceutical LLC January 13, 2022 ​ Stendra Tablets Confidential ​ Page 3 of 31 ​ Part A: Project Overview 1. Executive Summary of the Opportunity
12/34/56
EX-10.4
from 10-Q 6 pages Certain Information Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10)(iv) From This Document Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential
12/34/56